
iX Biopharma
Broker's Calls

Broker's Digest: Samudera, Raffles Medical, Multi-Chem, iX Biopharma, Hong Leong Asia
Samudera Shipping Line
Price target:
UOB Kay Hian "unrated"
Gainer from favourable freight rates
April 09, 2021
Broker's Calls
PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement
iX Biopharma remains a “buy” for PhillipCapital analyst Tay Wee Kuang, with an unchanged target price of 44.5 cents, as the specialty pharmaceutical company announced that it has entered into a str
April 08, 2021
Deals, joint ventures & alliances
iX Biopharma enters agreement with Chinese pharmaceutical distributor to tap China market
Specialty pharmaceutical company iX Biopharma has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co (CRPCG) to collaborate o
April 06, 2021
Broker's Calls

973 Brokers' Digest
ST Engineering
Price target:
RHB “buy” $4.25
CGS-CIMB “buy” $4.00
February 26, 2021
Broker's Calls
iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21
PhillipCapital is maintaining its “buy” call on Ix Biopharma, but at a lower target price of 44.5 cents.
February 22, 2021
New appointments
IX Biopharma appoints Eva Tan as CCO
Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer.
January 18, 2021
Positioning for the recovery

PhillipCapital eyes year-end STI at 3,200
Stock markets have remained volatile as countries take turns going into lockdowns to curb subsequent waves of the Covid-19 virus, creating near-term economic uncertainty.
December 24, 2020
Company in the news

iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore
iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20.
October 20, 2020
Broker's Calls

Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21
Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents.
October 02, 2020
Company in the news

iX Biopharma secures Australia's GMP licence for its testing laboratory
iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laborat
September 28, 2020